<DOC>
	<DOCNO>NCT00753545</DOCNO>
	<brief_summary>The primary purpose study determine AZD2281 effective well tolerate maintain improvement cancer previous platinum-based chemotherapy .</brief_summary>
	<brief_title>Assessment Efficacy AZD2281 Platinum Sensitive Relapsed Serous Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Female patient histologically diagnose serous ovarian cancer recurrent serous ovarian cancer . Patients must complete least 2 previous course platinum contain therapy ; patient must platinum sensitive penultimate chemo regimen . For last chemotherapy course prior enrolment study , patient must demonstrate objective stable maintain response ( partial complete response ) response need maintain completion chemotherapy . Patients must treat study within 8 wks completion final dose platinum contain regimen . Previous treatment PARP inhibitor include AZD2281 Patients low grade ovarian carcinoma . Patients drainage ascites final 2 cycle last chemotherapy regimen prior enrolment study Patients receive chemotherapy , radiotherapy ( except palliative reason ) , within 2 week last dose prior study entry ( long period depend defined characteristic agent use ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Serous ,</keyword>
	<keyword>Ovarian cancer ,</keyword>
	<keyword>PARP ,</keyword>
	<keyword>BRCA1 ,</keyword>
	<keyword>BRCA2 ,</keyword>
	<keyword>Poly ( ADP ribose ) polymerase ,</keyword>
	<keyword>Platinum sensitive ,</keyword>
	<keyword>Homologous Recombination Deficiency ( HRD )</keyword>
</DOC>